{"id":"thrombopoietin-receptor-agonist","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By activating the thrombopoietin receptor, Thrombopoietin Receptor Agonists mimic the action of thrombopoietin, a hormone that regulates platelet production in the bone marrow. This leads to increased platelet production and, potentially, improved outcomes in conditions characterized by low platelet counts.","oneSentence":"Thrombopoietin Receptor Agonists stimulate the thrombopoietin receptor to increase platelet production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:38.222Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thrombocytopenia"}]},"trialDetails":[{"nctId":"NCT07113743","phase":"PHASE1, PHASE2","title":"Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease","status":"ENROLLING_BY_INVITATION","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-09-10","conditions":"Chronic Granulomatous Disease (CGD)","enrollment":10},{"nctId":"NCT05772546","phase":"PHASE2","title":"Avatrombopag vs. Placebo for CIT in GI Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hanny Al-Samkari, MD","startDate":"2023-11-01","conditions":"Gastrointestinal Cancer, Gastrointestinal Neoplasms, Chemotherapy-Induced Thrombocytopenia","enrollment":60},{"nctId":"NCT06880081","phase":"PHASE1","title":"Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP)","status":"RECRUITING","sponsor":"Chongqing Peg-Bio Biopharm Co., Ltd.","startDate":"2025-03-07","conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":12},{"nctId":"NCT06521931","phase":"PHASE1","title":"A Study of PN20 for the Prevention of Chemotherapy-induced Thrombocytopenia in Lymphoma or Solid Tumor Patients","status":"COMPLETED","sponsor":"Chongqing Peg-Bio Biopharm Co., Ltd.","startDate":"2023-12-06","conditions":"Thrombocytopenia","enrollment":24},{"nctId":"NCT07421167","phase":"PHASE2","title":"A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-06-29","conditions":"Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES)","enrollment":164},{"nctId":"NCT07400341","phase":"PHASE2","title":"Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-01-31","conditions":"MDS (Myelodysplastic Syndrome), Aplastic Anemia (AA)","enrollment":66},{"nctId":"NCT05885555","phase":"PHASE2","title":"A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-08-16","conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":41},{"nctId":"NCT07321626","phase":"PHASE1","title":"Romiplostim N01 for Platelet Recovery After Haploidentical HSCT","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-06-01","conditions":"Acute Myeloid Leukemia, MDS (Myelodysplastic Syndrome), Delayed Platelet Engraftment","enrollment":130},{"nctId":"NCT07338422","phase":"NA","title":"HID-HSCT Versus IST as First-line Treatment for SAA","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-01-14","conditions":"Aplastic Anaemia","enrollment":116},{"nctId":"NCT07102849","phase":"","title":"Molecular and Clinical Analysis of Bone Marrow Failure: A Secondary Research Study","status":"ENROLLING_BY_INVITATION","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2025-09-09","conditions":"Bone Marrow Failure Disorders, VEXAS Syndrome, Hemoglobinurea, Paroxysmal","enrollment":1400},{"nctId":"NCT06287567","phase":"PHASE2","title":"Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP)","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-04-17","conditions":"Idiopathic Thrombocytopenic Purpura, Immune Thrombocytopenia","enrollment":17},{"nctId":"NCT07001254","phase":"PHASE2","title":"UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia","status":"NOT_YET_RECRUITING","sponsor":"Anjali Sharathkumar","startDate":"2026-08-01","conditions":"Aplastic Anemia","enrollment":15},{"nctId":"NCT06768619","phase":"NA","title":"Bioequivalence Study of Eltrombopag Olamine Tablets in Healthy Subjects in the Fed State","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-03-20","conditions":"Thrombocytopenia","enrollment":36},{"nctId":"NCT05466201","phase":"PHASE2, PHASE3","title":"The Use of Eltrombopag Post HSCT in BMFD","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-10-22","conditions":"Stem Cell Transplant Complications","enrollment":118},{"nctId":"NCT07214025","phase":"","title":"Safety and Efficacy of Romiplostim in Treatment of Chronic ITP in Children","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-11-01","conditions":"Romiplostim N01, ITP","enrollment":100},{"nctId":"NCT07133659","phase":"PHASE4","title":"Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study","status":"RECRUITING","sponsor":"Al-Mustansiriyah University","startDate":"2025-06-08","conditions":"ITP - Immune Thrombocytopenia","enrollment":25},{"nctId":"NCT04737850","phase":"PHASE3","title":"Hetrombopag for Pediatric Patients With Chronic Immune Thrombocytopenia","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-03-29","conditions":"Immune Thrombocytopenia","enrollment":100},{"nctId":"NCT04943042","phase":"","title":"An Observational, Multicenter Study to Evaluate the Use and Effectiveness of Doptelet® in Patients With ITP","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2022-02-22","conditions":"Immune Thrombocytopenia, ITP","enrollment":199},{"nctId":"NCT03119974","phase":"PHASE4","title":"Rate of Prolonged Response After Stopping Thrombopoietin-receptor Agonists Treatment in ITP","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-09-26","conditions":"Persistent or Chronic ITP","enrollment":48},{"nctId":"NCT07019545","phase":"PHASE2","title":"A PHASE II TRIAL AIMING TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA PREVIOUSLY TREATED WITH A THROMBOPOIETIN RECEPTOR AGONIST AND/OR RITUXIMAB AFTER CORTICOSTEROID FIRST-LINE THERAPY","status":"NOT_YET_RECRUITING","sponsor":"Hellenic Society of Hematology","startDate":"2025-06-20","conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":14},{"nctId":"NCT04346654","phase":"PHASE2","title":"A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITP","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-10-09","conditions":"Immune Thrombocytopenia (ITP)","enrollment":26},{"nctId":"NCT02298075","phase":"","title":"Response Rate and Duration After Discontinuation Thrombopoietin Receptor Agonists Primary Immune Thrombocytopenia","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2016-04","conditions":"Immune Thrombocytopenia","enrollment":148},{"nctId":"NCT06873672","phase":"","title":"Validation of the EQ-5D-Y-3L and EQ-5D-Y-5L for Paediatric Patients in China","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-04-01","conditions":"Quality of Life (QOL), Patient-Reported Outcome Measures (PROMs), Pneumonia Childhood","enrollment":360},{"nctId":"NCT06523088","phase":"PHASE1","title":"A Study of PN20 in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Chongqing Peg-Bio Biopharm Co., Ltd.","startDate":"2022-06-16","conditions":"Chemotherapy-induced Thrombocytopenia, Immune Thrombocytopenic Purpura","enrollment":27},{"nctId":"NCT06790888","phase":"NA","title":"Ripertamab Plus Eltrombopag vs. Eltrombopag in ITP Patients Post-Steroid Failure","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-02","conditions":"ITP - Immune Thrombocytopenia","enrollment":78},{"nctId":"NCT06768632","phase":"NA","title":"Bioequivalence Test of Eltrombopag Olamine Tablets in Humans Under Fasting State","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-01-02","conditions":"Thrombocytopenia","enrollment":36},{"nctId":"NCT01328587","phase":"PHASE2","title":"Eltrombopag for Moderate Aplastic Anemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2011-04-01","conditions":"Moderate Aplastic Anemia, Unilineage Bone Marrow Failure Disorders","enrollment":34},{"nctId":"NCT06693791","phase":"PHASE2","title":"Romiplostim N01 for Platelet Recovery in Adult Hematologic Malignancies Patients Undergoing UCBT","status":"RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2024-12-01","conditions":"Platelet Recovery After Umbilical Cord Blood Transplantation","enrollment":34},{"nctId":"NCT04812483","phase":"PHASE2","title":"Immunomodulation With Eltrombopag in ITP","status":"COMPLETED","sponsor":"University Children's Hospital Basel","startDate":"2022-09-01","conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":2},{"nctId":"NCT05931718","phase":"","title":"Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia","status":"RECRUITING","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2019-06-01","conditions":"Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, Chronic Idiopathic Neutropenia","enrollment":200},{"nctId":"NCT06568913","phase":"NA","title":"The Outcome of the Thrombopoietin Receptor Agonists in Pediatric Patient With Persistent or Chronic ITP Unresonsive to Steroids","status":"RECRUITING","sponsor":"Sohag University","startDate":"2024-07-14","conditions":"Persistent or Chronic ITP Not Respnding to Steroids","enrollment":100},{"nctId":"NCT04478227","phase":"EARLY_PHASE1","title":"TPO-Mimetic Use in Children for Hematopoietic Failure","status":"COMPLETED","sponsor":"Anjali Sharathkumar","startDate":"2020-08-18","conditions":"Bone Marrow Failure Disorders, Aplastic Anemia, Thrombocytopenia","enrollment":15},{"nctId":"NCT06478537","phase":"PHASE2","title":"TPO-RA Treatment on Immune Tolerance Induction of ITP Patients With Sustained Platelet Recovery After Treatment Termination","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-06-20","conditions":"Immune Thrombocytopenia","enrollment":56},{"nctId":"NCT05492409","phase":"PHASE3","title":"Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients","status":"COMPLETED","sponsor":"AO GENERIUM","startDate":"2022-03-28","conditions":"Idiopathic Thrombocytopenic Purpura","enrollment":160},{"nctId":"NCT06433830","phase":"PHASE2","title":"Hetrombopag for the Thrombocytopenia Induced by Concurrent Chemoradiotherapy","status":"RECRUITING","sponsor":"Sir Run Run Shaw Hospital","startDate":"2022-05-10","conditions":"Thrombocytopenia, Radiotherapy Side Effect","enrollment":50},{"nctId":"NCT06408324","phase":"","title":"Evaluation of the Use of Thrombopoietin Receptor Agonists in Adults With Primary ITP in Europe","status":"COMPLETED","sponsor":"European Research Consortium on ITP","startDate":"2022-11-24","conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":275},{"nctId":"NCT05220878","phase":"PHASE3","title":"Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITP","status":"COMPLETED","sponsor":"AO GENERIUM","startDate":"2021-09-09","conditions":"Idiopathic Thrombocytopenic Purpura","enrollment":160},{"nctId":"NCT00961064","phase":"PHASE2","title":"A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2011-03-15","conditions":"Myelodysplastic Syndromes, Thrombocytopenia","enrollment":30},{"nctId":"NCT06009965","phase":"PHASE4","title":"Efficacy of IST Combined With TPO-RA in the Treatment of AA and Establishment of a Recurrence Prediction System","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2023-01-20","conditions":"Aplastic Anemia, CSA, Drug Therapy","enrollment":210},{"nctId":"NCT05907499","phase":"PHASE3","title":"Decitabine for Poor Graft Function Post Allo-HSCT","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-07-01","conditions":"Poor Graft Function","enrollment":76},{"nctId":"NCT05669079","phase":"PHASE3","title":"Decitabine and Umbilical Cord Blood for Poor Graft Function Post Allo-HSCT","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-08-01","conditions":"Poor Graft Function","enrollment":100},{"nctId":"NCT05861297","phase":"PHASE4","title":"Immune Thrombocytopenia Management in Adults","status":"UNKNOWN","sponsor":"Nahda University","startDate":"2020-05-05","conditions":"Immune Thrombocytopenia Purpura","enrollment":467},{"nctId":"NCT05846529","phase":"","title":"Safety of Oral Thrombopoietin Receptor Agonist in Pediatric Chronic ITP","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-06","conditions":"Thrombopoietin Receptor Agonist","enrollment":100},{"nctId":"NCT01168921","phase":"PHASE2","title":"Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-11-03","conditions":"CLL, Leukemia","enrollment":23},{"nctId":"NCT05685420","phase":"PHASE3","title":"Extension Study of Herombopag for Pediatric Patients With Chronic Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-01-23","conditions":"Immune Thrombocytopenia","enrollment":117},{"nctId":"NCT03515096","phase":"PHASE3","title":"Eltrombopag vs. rhTPO to Increase Platelet Level After HSCT","status":"COMPLETED","sponsor":"Shenzhen Second People's Hospital","startDate":"2018-07-01","conditions":"Eltrombopag, Hematopoietic Stem Cell Transplantation, Thrombocytopenia","enrollment":98},{"nctId":"NCT05369377","phase":"PHASE2","title":"Zanubrutinib and Eltrombopag as Second-line Treatment in Adults With Primary Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-06-01","conditions":"Immune Thrombocytopenia","enrollment":150},{"nctId":"NCT03243656","phase":"PHASE4","title":"Eltrombopag & Cyclosporine in Children With Sever Aplastic Anemia","status":"COMPLETED","sponsor":"Assiut University","startDate":"2017-12-20","conditions":"Eltrombopag","enrollment":20},{"nctId":"NCT04701216","phase":"PHASE1","title":"A Trial of SHR8735 in Healthy Subjects","status":"COMPLETED","sponsor":"Atridia Pty Ltd.","startDate":"2021-02-11","conditions":"Healthy Volunteers","enrollment":48},{"nctId":"NCT04949009","phase":"","title":"Avatrombopag in the Treatment of Primary Immune Thrombocytopenia(ITP)","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2021-03-01","conditions":"Primary Immune Thrombocytopenia","enrollment":400},{"nctId":"NCT04896528","phase":"PHASE2","title":"Efficacy and Safety of Avatrombopag in Cancer Patients With Thrombocytopenia","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-06-06","conditions":"Thrombocytopenia, Avatrombopag","enrollment":30},{"nctId":"NCT00922883","phase":"PHASE2","title":"A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2009-05-29","conditions":"Anemia, Aplastic, Anemia, Hypoplastic, Thrombocytopenia","enrollment":43},{"nctId":"NCT01621204","phase":"PHASE3","title":"A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients","status":"COMPLETED","sponsor":"McMaster University","startDate":"2012-10","conditions":"Immune Thrombocytopenic Purpura","enrollment":74},{"nctId":"NCT02760251","phase":"PHASE4","title":"Immunomodulation With Romiplostim in Young Adults With ITP","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2016-04","conditions":"Immune Thrombocytopenia","enrollment":15},{"nctId":"NCT01762761","phase":"PHASE3","title":"Eltrombopag Phase III Study In Chinese Chronic ITP Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-02-18","conditions":"Purpura, Thrombocytopenic, Idiopathic and Hepatitis C","enrollment":155},{"nctId":"NCT01890746","phase":"PHASE2","title":"A Safety and Efficacy Study of Eltrombopag in Subjects With AML","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-09-05","conditions":"Acute Leukaemia","enrollment":148},{"nctId":"NCT02201290","phase":"PHASE3","title":"A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-06-18","conditions":"Purpura, Thrombocytopenic, Idiopathic","enrollment":9},{"nctId":"NCT00908037","phase":"PHASE2","title":"Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-30","conditions":"Purpura, Thrombocytopaenic, Idiopathic","enrollment":82},{"nctId":"NCT00828750","phase":"PHASE3","title":"Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-05","conditions":"Idiopathic Thrombocytopenic Purpura, Purpura, Thrombocytopenic, Idiopathic","enrollment":19},{"nctId":"NCT00903422","phase":"PHASE1","title":"Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-05-14","conditions":"Myelodysplastic Syndrome","enrollment":98},{"nctId":"NCT00358540","phase":"PHASE1","title":"Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-06-01","conditions":"Thrombocytopaenia","enrollment":18},{"nctId":"NCT00370331","phase":"PHASE3","title":"RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-11","conditions":"Purpura, Thrombocytopaenic, Idiopathic","enrollment":197},{"nctId":"NCT00643929","phase":"","title":"LENS - Long-term Eltrombopag Observational Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-02","conditions":"Purpura, Thrombocytopaenic, Idiopathic","enrollment":164},{"nctId":"NCT00102726","phase":"PHASE2","title":"SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-02","conditions":"Thrombocytopaenia","enrollment":183},{"nctId":"NCT01064336","phase":"","title":"Promacta Pregnancy Registry","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-03","conditions":"Purpura, Thrombocytopaenic, Idiopathic","enrollment":1},{"nctId":"NCT01147809","phase":"PHASE2","title":"Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-06","conditions":"Thrombocytopaenia","enrollment":130},{"nctId":"NCT01098487","phase":"PHASE4","title":"A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-05","conditions":"Purpura, Thrombocytopaenic, Idiopathic","enrollment":167},{"nctId":"NCT01520909","phase":"PHASE3","title":"Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-03","conditions":"Idiopathic Thrombocytopenic Purpura","enrollment":92},{"nctId":"NCT01481220","phase":"PHASE1","title":"Safety Study of Eltrombopag Combined With Azacitidine to Treat Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"Nordic MDS Group","startDate":"2011-10","conditions":"Myelodysplastic Syndrome, Thrombocytopenia","enrollment":12},{"nctId":"NCT00102739","phase":"PHASE2","title":"SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-02","conditions":"Purpura, Thrombocytopaenic, Idiopathic","enrollment":99},{"nctId":"NCT01618734","phase":"","title":"Eltrombopag and Romiplostim Used Alternatively in Patients With Immune Thrombopenia (ITP): Efficacy and Safety.","status":"COMPLETED","sponsor":"Henri Mondor University Hospital","startDate":"2012-01","conditions":"Immune Thrombocytopenia, Thrombopoietin Receptor Agonist","enrollment":50},{"nctId":"NCT00110799","phase":"PHASE2","title":"SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-04","conditions":"Hepatitis C, Chronic, Hepatitis C, Thrombocytopenia","enrollment":75},{"nctId":"NCT00888901","phase":"PHASE4","title":"Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag","status":"COMPLETED","sponsor":"Ingrid Pabinger, MD","startDate":"2009-05","conditions":"Idiopathic Thrombocytopenic Purpura","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":685,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Eltrombopag / Avatrombopag"],"phase":"phase_3","status":"active","brandName":"Thrombopoietin Receptor Agonist","genericName":"Thrombopoietin Receptor Agonist","companyName":"The First Affiliated Hospital of Soochow University","companyId":"the-first-affiliated-hospital-of-soochow-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Thrombopoietin Receptor Agonists stimulate the thrombopoietin receptor to increase platelet production. Used for Thrombocytopenia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}